Joan E. Herman - 10 Jun 2022 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Jun 2022, 18:03:55 UTC
Prior SEC filing
09 May 2022
Next SEC filing
06 Jul 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
By: Patrick R. O'Neil, attorney-in-fact For: Joan E. Herman

Key filing fact

Joan E. Herman filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 14 Jun 2022.

Key facts

  • This page summarizes Joan E. Herman's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 14 Jun 2022, 18:03.

Change

  • Previous filing in this sequence was filed on 09 May 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+3,555
Change %
+22%
Price
$0.000000
Shares after
19,555
Date
10 Jun 2022
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-3,555
Change %
-22%
Price
$0.000000
Shares after
12,442
Date
10 Jun 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,555
Exercise price
$0.000000
Footnotes
F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

Footnote F2

Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

Footnote F3

Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .